Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

Science Translational Medicine

Volumn 9, Issue 402, 2017, Pages

  Ali, Mohammad Alhadj ^a   Liu, Yuk Fun ^b,c   Arif, Sefina ^b   Tatovic, Danijela ^a   Shariff, Hina ^b   Gibson, Vivienne B ^b   Yusuf, Norkhairin ^b   Baptista, Roman ^b,c   Eichmann, Martin ^b   Petrov, Nedyalko ^c   Heck, Susanne ^c   Yang, Jennie H M ^b   Tree, Timothy I M ^b   Irma, Pujol Autonell ^b   Yeo, Lorraine ^b   Baumard, Lucas R ^b   Stenson, Rachel ^a   Howell, Alex ^a   Clark, Alison ^a   Boult, Zoe ^d   Powrie, Jake ^c   Adams, Laura ^c   Wong, Florence S ^a   Luzio, Stephen ^e   Dunseath, Gareth ^e   Green, Kate ^f   OKeefe, Alison ^f   Bayly, Graham ^f   Thorogood, Natasha ^f   Andrews, Robert ^f   Leech, Nicola ^g   Joseph, Frank ^h   Nair, Sunil ^h   Seal, Susan ^h   Cheung, Hoyee ^h   Beam, Craig ⁱ   Hills, Robert ^a   Peakman, Mark ^b,c,j   Dayan, Colin M ^a   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e SWANSEA UNIVERSITY   (United Kingdom)

^f UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^g NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h Countess of Chester Hospital NHS Foundation Trust ^*  (United Kingdom)

ⁱ WESTERN MICHIGAN UNIVERSITY   (United States)

^j KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; C PEPTIDE; PEPTIDE; PROINSULIN;

ADOLESCENT; ADULT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOANTIBODIES; AUTOANTIGENS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MALE; MIDDLE AGED; PEPTIDES; PROINSULIN; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 85027408203     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf7779     Document Type: Article

References (34)

1. R. A. Oram, T. J. McDonald, B. M. Shields, M. M. Hudson, M. H. Shepherd, S. Hammersley, E. R. Pearson, A. T. Hattersley; UNITED Team, Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 38, 323-328 (2015).
2. J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, M. W. Steffes, C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve b-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes 53, 250-264 (2004).
3. S. J. Livingstone, D. Levin, H. C. Looker, R. S. Lindsay, S. H. Wild, N. Joss, G. Leese, P. Leslie, R. J. McCrimmon, W. Metcalfe, J. A. McKnight, A. D. Morris, D. W. M. Pearson, J. R. Petrie, S. Philip, N. A. Sattar, J. P. Traynor, H. M. Colhoun; Scottish Diabetes Research Network Epidemiology Group; Scottish Renal Registry, Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 313, 37-44 (2015).
4. C. C. Patterson, E. Gyürüs, J. Rosenbauer, O. Cinek, A. Neu, E. Schober, R. C. Parslow, G. Joner, J. Svensson, C. Castell, P. J. Bingley, E. Schoenle, P. Jarosz-Chobot, B. Urbonaité, U. Rothe, C. Krzisnik, C. Ionescu-Tirgoviste, I. Weets, M. Kocova, G. Stipancic, M. Samardzic, C. E. de Beaufort, A. Green, G. G. Dahlquist, G. Soltész, Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: Evidence of non-uniformity over time in rates of increase. Diabetologia 55, 2142-2147 (2012).
5. J. M. Lachin, P. McGee, J. P. Palmer; DCCT/EDIC Research Group, Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 63, 739-748 (2014).
6. A. M. Brooks, R. Oram, P. Home, N. Steen, J. A. M. Shaw, Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation. Diabetes Care 38, 105-112 (2015).
7. J. S. Sørensen, J. Johannesen, F. Pociot, K. Kristensen, J. Thomsen, N. T. Hertel, P. Kjaersgaard, C. Brorsson, N. H. Birkebaek; Danish Society for Diabetes in Childhood and Adolescence, Residual b-cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care 36, 3454-3459 (2013).
8. S. Arif, T. I. Tree, T. P. Astill, J. M. Tremble, A. J. Bishop, C. M. Dayan, B. O. Roep, M. Peakman, Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113, 451-463 (2004).
9. A. Skowera, R. J. Ellis, R. Varela-Calviño, S. Arif, G. C. Huang, C. Van-Krinks, A. Zaremba, C. Rackham, J. S. Allen, T. I. M. Tree, M. Zhao, C. M. Dayan, A. K. Sewell, W. W. Unger, J. W. Drijfhout, F. Ossendorp, B. O. Roep, M. Peakman, CTLs are targeted to kill b cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118, 3390-3402 (2008).
10. S. Arif, F. Moore, K. Marks, T. Bouckenooghe, C. M. Dayan, R. Planas, M. Vives-Pi, J. Powrie, T. Tree, P. Marchetti, G. C. Huang, E. N. Gurzov, R. Pujol-Borrell, D. L. Eizirik, M. Peakman, Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated b-cell death. Diabetes 60, 2112-2119 (2011).
11. J. M. Lawson, J. Tremble, C. Dayan, H. Beyan, R. D. G. Leslie, M. Peakman, T. I. M. Tree, Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353-359 (2008).
12. S. Lindley, C. M. Dayan, A. Bishop, B. O. Roep, M. Peakman, T. I. M. Tree, Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 54, 92-99 (2005).
13. L. G. Petrich de Marquesini, J. Fu, K. J. Connor, A. J. Bishop, N. E. McLintock, C. Pope, F. S. Wong, C. M. Dayan, IFN-g and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 53, 1451-1460 (2010).
14. T. I. M/ Tree, J. Lawson, H. Edwards, A. Skowera, S. Arif, B. O. Roep, M. Peakman, Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59, 1451-1460 (2010).
15. M. Larché, D. C. Wraith, Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69-S76 (2005).
16. S. L. Thrower, L. James, W. Hall, K. M. Green, S. Arif, J. S. Allen, C. Van-Krinks, B. Lozanoska-Ochser, L. Marquesini, S. Brown, F. S. Wong, C. M. Dayan, M. Peakman, Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man phase I safety study. Clin. Exp. Immunol. 155, 156-165 (2009).
17. H. B. Mortensen, P. Hougaard, P. Swift, L. Hansen, R. W. Holl, H. Hoey, H. Bjoerndalen, C. de Beaufort, F. Chiarelli, T. Danne, E. J. Schoenle, J. Åman; Hvidoere Study Group on Childhood Diabetes, New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32, 1384-1390 (2009).
18. C. A. Beam, S. E. Gitelman, J. P. Palmer; Type 1 Diabetes TrialNet Study Group, Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes 63, 3120-3127 (2014).
19. P. Couroux, D. Patel, K. Armstrong, M. Larché, R. P. Hafner, Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin. Exp. Allergy 45, 974-981 (2015).
20. D. Patel, P. Couroux, P. Hickey, A. M. Salapatek, P. Laidler, M. Larché, R. P. Hafner, Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. J. Allergy Clin. Immunol. 131, 103-109.e7 (2013).
21. V. B. Gibson, T. Nikolic, V. Q. Pearce, J. Demengeot, B. O. Roep, M. Peakman, Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin. Exp. Immunol. 182, 251-260 (2015).
22. M. Peakman, E. J. Stevens, T. Lohmann, P. Narendran, J. Dromey, A. Alexander, A. J. Tomlinson, M. Trucco, J. C. Gorga, R. M. Chicz, Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J. Clin. Invest. 104, 1449-1457 (1999).
23. A.-H. Lee, K. Heidtman, G. S. Hotamisligil, L. H. Glimcher, Dual and opposing roles of the unfolded protein response regulated by IRE1a and XBP1 in proinsulin processing and insulin secretion. Proc. Natl. Acad. Sci. U.S.A. 108, 8885-8890 (2011).
24. R. A. Watkins, C. Evans-Molina, J. K. Terrell, K. H. Day, L. Guindon, I. A. Restrepo, R. G. Mirmira, J. S. Blum, L. A. DiMeglio, Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes. Transl. Res. 168, 96-106.e1 (2016).
25. M. E. Røder, M. Knip, S. G. Hartling, J. Karjalainen, H. K. Akerblom, C. Binder, Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. The Childhood Diabetes in Finland Study Group. J. Clin. Endocrinol. Metab. 79, 1570-1575 (1994).
26. O. Snorgaard, S. G. Hartling, C. Binder, Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33, 36-42 (1990).
27. I. Kochetkova, S. Golden, K. Holderness, G. Callis, D. W. Pascual, IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J. Immunol. 184, 7144-7153 (2010).
28. M. Yadav, S. Stephan, J. A. Bluestone, Peripherally induced Tregs-Role in immune homeostasis and autoimmunity. Front. Immunol. 4, 232 (2013).
29. F. S. Kleijwegt, S. Laban, G. Duinkerken, A. M. Joosten, B. P. C. Koeleman, T. Nikolic, B. O. Roep, Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J. Immunol. 187, 6357-6364 (2011).
30. A. Skowera, K. Ladell, J. E. McLaren, G. Dolton, K. K. Matthews, E. Gostick, D. Kronenberg-Versteeg, M. Eichmann, R. R. Knight, S. Heck, J. Powrie, P. J. Bingley, C. M. Dayan, J. J. Miles, A. K. Sewell, D. A. Price, M. Peakman, b-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes 64, 916-925 (2015).
31. R. A. Insel, J. L. Dunne, M. A. Atkinson, J. L. Chiang, D. Dabelea, P. A. Gottlieb, C. J. Greenbaum, K. C. Herold, J. P. Krischer, Å. Lernmark, R. E. Ratner, M. J. Rewers, D. A. Schatz, J. S. Skyler, J. M. Sosenko, A.-G. Ziegler, Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38, 1964-1974 (2015).
32. C. J. Greenbaum, T. Mandrup-Poulsen, P. F. McGee, T. Battelino, B. Haastert, J. Ludvigsson, P. Pozzilli, J. M. Lachin, H. Kolb; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group, Mixed-meal tolerance test versus glucagon stimulation test for the assessment of b-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31, 1966-1971 (2008).
33. K. C. Herold, B. Brooks-Worrell, J. Palmer, H. M. Dosch, M. Peakman, P. Gottlieb, H. Reijonen, S. Arif, L. M. Spain, C. Thompson, J. M. Lachin; Type 1 Diabetes TrialNet Research Group, Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 58, 2588-2595 (2009).
34. J. H. Levine, E. F. Simonds, S. C. Bendall, K. L. Davis, E.-a. D. Amir, M. D. Tadmor, O. Litvin, H. G. Fienberg, A. Jager, E. R. Zunder, R. Finck, A. L. Gedman, I. Radtke, J. R. Downing, D. Pe'er, G. P. Nolan, Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184-197 (2015).